期刊文献+

The CARMA3-BCL10-MALT1 (CBM) complex contributes to DNA damage-induced NF-κB activation and cell survival 被引量:5

The CARMA3-BCL10-MALT1 (CBM) complex contributes to DNA damage-induced NF-κB activation and cell survival
原文传递
导出
摘要 Dear Editor,Chemotherapy is one of major means for cancer treatments, and many of chemotherapeutic drugs are DNA damaging agents that reduce tumor growth through triggering cancer cell apoptosis or necrosis. Following DNA damage, ataxia telangiectasia mutated (ATM), a protein kinase, was acti- vated and a cytosolic complex containing ATM, NEMO, RIP1 were formed (Biton and Ashkenazi, 2011). Dear Editor,Chemotherapy is one of major means for cancer treatments, and many of chemotherapeutic drugs are DNA damaging agents that reduce tumor growth through triggering cancer cell apoptosis or necrosis. Following DNA damage, ataxia telangiectasia mutated (ATM), a protein kinase, was acti- vated and a cytosolic complex containing ATM, NEMO, RIP1 were formed (Biton and Ashkenazi, 2011).
出处 《Protein & Cell》 SCIE CAS CSCD 2017年第11期856-860,共5页 蛋白质与细胞(英文版)
关键词 CARMA3-BCL10-MALT1 (CBM) complex contributes to DNA damage-induced NF-κB activation cell survival CARMA3-BCL10-MALT1 (CBM) complex contributes to DNA damage-induced NF-κB activation cell survival
  • 相关文献

二级参考文献162

  • 1Compagno M, Lim WK, Grunn A, et al. Mutations ofmultiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature 2009; 459:717-721.
  • 2Montesinos-Rongen M, Schmitz R, Brunn A, et al. Mutations of CARDll but not TNFAIP3 may activate the NF-kappaB pathway in primary CNS lymphoma. Acta Neulvpatho12010; 120:529-535.
  • 3Lamason RL, McCully RR, Lew SM, Pomerantz JL. Oncogenic CARD 11 Mutations Induce Hyperactive Signaling by Disrupting Autoinhibition by the PKC-Responsive Inhibitory Domain. Biochemistry 2010; 49:8240-8250.
  • 4Hailfinger S, Lenz G, Ngo V, et al. Essential role of MALT1 protease activity in activated B cell-like diffuse large B-cell lymphoma. ProcNatlAcadSci USA 2009; 106:19946-19951.
  • 5Ferch U, Kloo B, Gewies A, et al. Inhibition of MALT1 protease activity is selectively toxic for activated B celllike diffuse large B cell lymphoma cells. J Exp Med 2009; 206:2313-2320.
  • 6Davis RE, Brown KD, Siebenlist U, Staudt LM. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med2001; 194:1861-1874.
  • 7Lam LT, Davis RE, Pierce J, et al. Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profi- ling. Clin Cancer Res 2005; 11:28-40.
  • 8Grabiner BC, Blonska M, Lin PC, et al. CARMA3 deficiency abrogates G protein-coupled receptor-induced NF-{kappa}B activation. Genes Dev 2007; 21:984-996.
  • 9Lefkowitz RJ. Historical review: a brief history and personal retrospective of seven-transmembrane receptors. Trends Pharmaeol Sci 2004; 25:413-422.
  • 10Mills GB, Moolenaar WH. The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer 2003; 3:582-591.

共引文献14

同被引文献20

引证文献5

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部